Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial

K. Gowin, T. Jain, H. Kosiorek, R. Tibes, J. Camoriano, J. Palmer, Ruben Mesa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Polycythemia vera, essential thrombocytosis, and myelofibrosis are chronic Philadelphia-negative myeloproliferative neoplasms that are characterized by clonal hematopoiesis, splenomegaly, risk of hemorrhagic and thrombotic sequelae, and profound symptom burden. We review the outcomes of 75 myeloproliferative neoplasm patients treated with pegylated interferon alpha 2a off study at an academic medical center. In the 56 treated polycythemia vera and essential thrombocytosis patients, a complete or partial response was obtained in 78.6% of patients per ELN/IWG-MRT revised criteria, with >80% of polycythemia vera patients becoming phlebotomy independent and 60% of essential thrombocytosis patients having platelet normalization with therapy. In the 19 treated myelofibrosis patients, stable disease was seen in 63.2% of patients. Vascular events occurred in 2/75 (2.6%) of treated patients while on therapy. Grade 3 toxicity was uncommon with leukopenia noted in 1 patient (1.3%). The most common adverse event overall was grade 1 fatigue in 18.7%. This retrospective single center analysis demonstrates pegylated interferon alpha 2a is active and well-tolerated therapy outside the support of a clinical trial. These results substantiate the previously reported efficacy of pegylated interferon alpha 2a in myeloproliferative neoplasms. Further prospective and randomized clinical trial data is required to better delineate pegylated interferon alpha 2a's use in myeloproliferative disease, with emphasis placed on comprehensive molecular characterization, allelic burden quantification, and measurement of histologic response.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalLeukemia Research
Volume54
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Clinical Trials
Thrombocytosis
Neoplasms
Polycythemia Vera
Primary Myelofibrosis
peginterferon alfa-2a
Phlebotomy
Splenomegaly
Hematopoiesis
Leukopenia
Fatigue
Blood Vessels
Therapeutics
Blood Platelets
Randomized Controlled Trials

Keywords

  • Essential thrombocytosis
  • Myelofibrosis
  • Myeloproliferative neoplasms
  • Pegylated interferon
  • Polycythemia vera

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. / Gowin, K.; Jain, T.; Kosiorek, H.; Tibes, R.; Camoriano, J.; Palmer, J.; Mesa, Ruben.

In: Leukemia Research, Vol. 54, 01.03.2017, p. 73-77.

Research output: Contribution to journalArticle

Gowin, K. ; Jain, T. ; Kosiorek, H. ; Tibes, R. ; Camoriano, J. ; Palmer, J. ; Mesa, Ruben. / Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. In: Leukemia Research. 2017 ; Vol. 54. pp. 73-77.
@article{8ac2a5b40c434560a119456ba9159d2a,
title = "Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial",
abstract = "Polycythemia vera, essential thrombocytosis, and myelofibrosis are chronic Philadelphia-negative myeloproliferative neoplasms that are characterized by clonal hematopoiesis, splenomegaly, risk of hemorrhagic and thrombotic sequelae, and profound symptom burden. We review the outcomes of 75 myeloproliferative neoplasm patients treated with pegylated interferon alpha 2a off study at an academic medical center. In the 56 treated polycythemia vera and essential thrombocytosis patients, a complete or partial response was obtained in 78.6{\%} of patients per ELN/IWG-MRT revised criteria, with >80{\%} of polycythemia vera patients becoming phlebotomy independent and 60{\%} of essential thrombocytosis patients having platelet normalization with therapy. In the 19 treated myelofibrosis patients, stable disease was seen in 63.2{\%} of patients. Vascular events occurred in 2/75 (2.6{\%}) of treated patients while on therapy. Grade 3 toxicity was uncommon with leukopenia noted in 1 patient (1.3{\%}). The most common adverse event overall was grade 1 fatigue in 18.7{\%}. This retrospective single center analysis demonstrates pegylated interferon alpha 2a is active and well-tolerated therapy outside the support of a clinical trial. These results substantiate the previously reported efficacy of pegylated interferon alpha 2a in myeloproliferative neoplasms. Further prospective and randomized clinical trial data is required to better delineate pegylated interferon alpha 2a's use in myeloproliferative disease, with emphasis placed on comprehensive molecular characterization, allelic burden quantification, and measurement of histologic response.",
keywords = "Essential thrombocytosis, Myelofibrosis, Myeloproliferative neoplasms, Pegylated interferon, Polycythemia vera",
author = "K. Gowin and T. Jain and H. Kosiorek and R. Tibes and J. Camoriano and J. Palmer and Ruben Mesa",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.leukres.2017.01.006",
language = "English (US)",
volume = "54",
pages = "73--77",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial

AU - Gowin, K.

AU - Jain, T.

AU - Kosiorek, H.

AU - Tibes, R.

AU - Camoriano, J.

AU - Palmer, J.

AU - Mesa, Ruben

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Polycythemia vera, essential thrombocytosis, and myelofibrosis are chronic Philadelphia-negative myeloproliferative neoplasms that are characterized by clonal hematopoiesis, splenomegaly, risk of hemorrhagic and thrombotic sequelae, and profound symptom burden. We review the outcomes of 75 myeloproliferative neoplasm patients treated with pegylated interferon alpha 2a off study at an academic medical center. In the 56 treated polycythemia vera and essential thrombocytosis patients, a complete or partial response was obtained in 78.6% of patients per ELN/IWG-MRT revised criteria, with >80% of polycythemia vera patients becoming phlebotomy independent and 60% of essential thrombocytosis patients having platelet normalization with therapy. In the 19 treated myelofibrosis patients, stable disease was seen in 63.2% of patients. Vascular events occurred in 2/75 (2.6%) of treated patients while on therapy. Grade 3 toxicity was uncommon with leukopenia noted in 1 patient (1.3%). The most common adverse event overall was grade 1 fatigue in 18.7%. This retrospective single center analysis demonstrates pegylated interferon alpha 2a is active and well-tolerated therapy outside the support of a clinical trial. These results substantiate the previously reported efficacy of pegylated interferon alpha 2a in myeloproliferative neoplasms. Further prospective and randomized clinical trial data is required to better delineate pegylated interferon alpha 2a's use in myeloproliferative disease, with emphasis placed on comprehensive molecular characterization, allelic burden quantification, and measurement of histologic response.

AB - Polycythemia vera, essential thrombocytosis, and myelofibrosis are chronic Philadelphia-negative myeloproliferative neoplasms that are characterized by clonal hematopoiesis, splenomegaly, risk of hemorrhagic and thrombotic sequelae, and profound symptom burden. We review the outcomes of 75 myeloproliferative neoplasm patients treated with pegylated interferon alpha 2a off study at an academic medical center. In the 56 treated polycythemia vera and essential thrombocytosis patients, a complete or partial response was obtained in 78.6% of patients per ELN/IWG-MRT revised criteria, with >80% of polycythemia vera patients becoming phlebotomy independent and 60% of essential thrombocytosis patients having platelet normalization with therapy. In the 19 treated myelofibrosis patients, stable disease was seen in 63.2% of patients. Vascular events occurred in 2/75 (2.6%) of treated patients while on therapy. Grade 3 toxicity was uncommon with leukopenia noted in 1 patient (1.3%). The most common adverse event overall was grade 1 fatigue in 18.7%. This retrospective single center analysis demonstrates pegylated interferon alpha 2a is active and well-tolerated therapy outside the support of a clinical trial. These results substantiate the previously reported efficacy of pegylated interferon alpha 2a in myeloproliferative neoplasms. Further prospective and randomized clinical trial data is required to better delineate pegylated interferon alpha 2a's use in myeloproliferative disease, with emphasis placed on comprehensive molecular characterization, allelic burden quantification, and measurement of histologic response.

KW - Essential thrombocytosis

KW - Myelofibrosis

KW - Myeloproliferative neoplasms

KW - Pegylated interferon

KW - Polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=85009918581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009918581&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2017.01.006

DO - 10.1016/j.leukres.2017.01.006

M3 - Article

C2 - 28113109

AN - SCOPUS:85009918581

VL - 54

SP - 73

EP - 77

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -